Medicure Inc’s 2026 first-quarter update signals steady operations with no major shifts in financial or operating metrics, reinforcing the company’s reliance on a few major US customers and outsourced manufacturing partners. Its business model splits between pharmaceutical product distribution, anchored by AGGRASTAT® and ZYPITAMAG®, and retail plus mail order pharmacy services. The company faces growth constraints primarily from customer concentration risks, regulatory complexities, and supply chain dependencies. While patents and FDA approvals provide moderate barriers to entry, these advantages are offset by vulnerabilities related to limited internal manufacturing and heavy reliance on a narrow customer base.